- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.